Dotinurad (FYU-981)

Why It Matters

Dotinurad offers a novel oral gout treatment with an improved safety profile, potentially reshaping the urate‑lowering drug market and providing clinicians with an alternative to allopurinol.

Key Takeaways

• Approved in Japan, China as Urece® for gout
• Optimized from benzbromarone to reduce hepatotoxicity
• Phase 3 US trials compare against allopurinol
• Targets URAT1 to increase uric acid excretion
• Primary completion expected late 2027

Pulse Analysis

Gout remains a prevalent inflammatory arthritis driven by elevated serum urate, and current management relies heavily on xanthine oxidase inhibitors such as allopurinol. While effective, these agents can provoke hypersensitivity reactions and are unsuitable for patients with renal impairment, prompting a search for alternative urate‑lowering strategies. URAT1 inhibitors, which block renal reabsorption of uric acid, have emerged as a promising class, offering a mechanistic shift from production inhibition to enhanced excretion.

Dotinurad distinguishes itself by being derived from the legacy uricosuric benzbromarone, a compound historically linked to rare but serious hepatotoxicity. Through targeted molecular redesign, Crystalys Therapeutics eliminated the toxic moiety while preserving high affinity for the URAT1 transporter, resulting in robust serum urate reductions observed in Japanese and Chinese patient cohorts. The drug’s approval as Urece® in these markets validates its efficacy and safety, providing a real‑world data foundation for broader regulatory pursuits.

In the United States, dotinurad is now in late‑stage development, with two Phase 3 trials directly comparing its performance to allopurinol in diverse gout populations. If the trials meet their endpoints, dotinurad could capture market share from entrenched therapies, especially among patients intolerant to existing options. The anticipated 2027 primary completion aligns with a growing demand for safer, oral urate‑lowering agents, positioning dotinurad as a potential game‑changer in the competitive gout treatment landscape.